Table 1 Relationship between SYNPO2 expression and cancers
Types of cancer | Treatment | SYNPO2 | Signaling pathway | Biological function |
|---|---|---|---|---|
Prostate cancer | SYNPO2 inactivation and deletion | Low | NA | |
Overexpression | Up | Interaction with zyxin | Inhibiting tumor growth and metastasis [9] | |
NA | To promote lamellipodia formation and cell migration [10, 18] | |||
siSYNPO2 | Low | NA | ||
Phosphorylation of SYNPO2 | NA | NA | Cell growth and motility [23] | |
Neuroblastoma | DKK1 induce SYNPO2 expression | Up | NA | Growth suppressive effect [5] |
Hepatocellular carcinoma | Cytoplasmic translocation | Low | CaN/SYNPO2/F-actin axis | Metastasis [6] |
Cervical cancer | miRNAs downregulated SYNPO2 | Low | ER;PI3K/AKT;EMT signaling pathway | Inhibiting DNA damage and cell cycle [7] |
Colorectal cancer | Overexpression | Up | Inhibiting proliferation and migration [47]; Inhibiting cell proliferation [8] | |
Down-regulation of SYNPO2 | Low | ER, PI3K/AKT, EMT signaling pathway | Inhibiting DNA damage and cell cycle [7] | |
Azacitidine | Low | NA | Associated with tumor stage and survival [58] | |
Melanoma | Methylation | Low | NA | Recurrence [13] |
Endogenous | Low | TME | Anti-PD-1 therapy [56] | |
Kidney cancer | Methylation | Low | NA | Distant metastasis and survival [14] |
Triple negative breast cancer | Up | Inhibiting stem cell-like properties, clinical stage, survival, lymph node metastasis [45, 46, 51]; | ||
LncRNA | Low | NA | Inhibiting relapse-free survival of TNBC [12] | |
Bladder cancer | Methylation | Low | NA | |
Endogenous | Low | NA | Inhibiting survival and an increased recurrence rate [11] |